Cyclopiazonic acid
(Synonyms: 环匹阿尼酸,NSC 117181) 目录号 : GC10268A mycotoxin and SERCA inhibitor
Cas No.:18172-33-3
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Cyclopiazonic acid is a mycotoxin produced by molds including certain species of Penicillium and Aspergillus. Its toxicity is linked to its ability to specifically and reversibly inhibit sarco-endoplasmic reticulum Ca2+-ATPases (SERCA; IC50 = 0.6 μM).[1],[2] Cyclopiazonic acid does not inhibit a wide variety of other types of membrane-bound ATPases. It effectively inhibits SERCA in intact tissue, in smooth muscle and endothelium, as well as in isolated cells.[3],[4]
References
[1]. Seidler, N.W., Jona, I., Vegh, M., et al. Cyclopiazonic acid is a specific inhibitor of the Ca2+-ATPase of sarcoplasmic reticulum. The Journal of Biological Chemisty 264(30), 17816-17823 (1989).
[2]. Uyama, Y., Imaizumi, Y., and Watanabe, M. Effects of cyclopiazonic acid, a novel Ca2+-ATPase inhibitor, on contractile responses in skinned ileal smooth muscle. British Journal of Pharmacology 106, 208-214 (1992).
[3]. Mumtaz, S., Burdyga, G., Borisova, L., et al. The mechanism of agonist induced Ca2+ signalling in intact endothelial cells studied confocally in in situ arteries. Cell Calcium 49(1-4), 66-77 (2011).
[4]. Berra-Romani, R., Raqeeb, A., Torres-Jácome, J., et al. The mechanism of injury-induced intracellular calcium concentration oscillations in the endothelium of excised rat aorta. Journal of Vascular Research 49, 65-76 (2012).
| Cas No. | 18172-33-3 | SDF | |
| 别名 | 环匹阿尼酸,NSC 117181 | ||
| 化学名 | (6aS,11aR,11bR)-10-acetyl-11-hydroxy-7,7-dimethyl-6a,7,11a,11b-tetrahydro-2H-pyrrolo[1',2':2,3]isoindolo[4,5,6-cd]indol-9(6H)-one | ||
| Canonical SMILES | OC1=C(C(C)=O)C(N2C(C)(C)[C@@H](CC3=C4C5=CNC4=CC=C3)[C@H]5[C@@H]21)=O | ||
| 分子式 | C20H20N2O3 | 分子量 | 336.39 |
| 溶解度 | DMF: 30 mg/ml,DMSO: 20 mg/ml,DMSO:PBS(pH7.2) (1:1): 0.5 mg/ml | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.9727 mL | 14.8637 mL | 29.7274 mL |
| 5 mM | 0.5945 mL | 2.9727 mL | 5.9455 mL |
| 10 mM | 0.2973 mL | 1.4864 mL | 2.9727 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。